WallStSmart

Adapthealth Corp (AHCO)vsBoston Scientific Corp (BSX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 513% more annual revenue ($21.07B vs $3.44B). BSX leads profitability with a 16.6% profit margin vs -11.8%. BSX earns a higher WallStSmart Score of 62/100 (C+).

AHCO

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 3.0Value: 6.7Quality: 4.0
Piotroski: 4/9Altman Z: 0.95

BSX

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 6.7Quality: 6.0
Piotroski: 5/9Altman Z: 1.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHCOUndervalued (+66.4%)

Margin of Safety

+66.4%

Fair Value

$31.37

Current Price

$7.87

$23.50 discount

UndervaluedFair: $31.37Overvalued
BSXOvervalued (-9.2%)

Margin of Safety

-9.2%

Fair Value

$39.15

Current Price

$44.23

$5.08 premium

UndervaluedFair: $39.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHCO1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

BSX5 strengths · Avg: 8.2/10
Market CapQuality
$60.84B9/10

Large-cap with strong market position

PEG RatioValuation
0.638/10

Growing faster than its price suggests

P/E RatioValuation
17.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.2%8/10

Strong operational efficiency at 20.2%

Areas to Watch

AHCO4 concerns · Avg: 2.8/10
Market CapQuality
$1.00B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Debt/EquityHealth
1.673/10

Elevated debt levels

Return on EquityProfitability
-33.2%2/10

ROE of -33.2% — below average capital efficiency

BSX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

EPS GrowthGrowth
-21.5%2/10

Earnings declined 21.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : AHCO

The strongest argument for AHCO centers on Price/Book. Revenue growth of 10.9% demonstrates continued momentum.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.

Bear Case : AHCO

The primary concerns for AHCO are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.67 is elevated, increasing financial risk.

Bear Case : BSX

The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.

Key Dynamics to Monitor

AHCO profiles as a turnaround stock while BSX is a value play — different risk/reward profiles.

AHCO carries more volatility with a beta of 1.32 — expect wider price swings.

AHCO is growing revenue faster at 10.9% — sustainability is the question.

BSX generates stronger free cash flow (868M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (62/100 vs 47/100), backed by strong 16.6% margins. AHCO offers better value entry with a 66.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adapthealth Corp

HEALTHCARE · MEDICAL DEVICES · USA

AdaptHealth Corp. The company is headquartered in Plymouth Meeting, Pennsylvania.

Visit Website →

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?